Cash Flow Statement

Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Zentalis Pharmaceuticals (ZNTL) Asset Writedowns and Impairment (2023 - 2025)

Zentalis Pharmaceuticals has reported Asset Writedowns and Impairment over the past 2 years, most recently at $3.0 million for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $3.0 million; the TTM value through Mar 2026 reached $3.0 million, up 159.03%, while the annual FY2025 figure was $4.1 million, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2025 was $3.0 million at Zentalis Pharmaceuticals, up from $1.2 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $5.0 million in Q1 2023 and troughed at $1.2 million in Q1 2025.